Background: Neglected tropical diseases (NTDs) are closely related to poverty and affect
over a billion people in developing countries. The unmet treatment needs cause high …

Current tuberculosis (TB) drug development efforts are not sufficient to end the global TB
epidemic. Recent efforts have focused on the development of whole-cell screening assays …

Drug-resistant bacteria pose an increasingly serious threat to mankind all over the world.
However, the currently available clinical treatments do not meet the urgent demand …

In recent years, whole-cell-based screens for novel small molecule inhibitors active against
Mycobacterium tuberculosis in culture followed by the whole-genome sequencing of …

Antibacterial drug development suffers from a paucity of targets whose inhibition kills
replicating and nonreplicating bacteria. The latter include phenotypically dormant cells …

ABSTRACT para-Aminosalicylic acid (PAS) entered clinical use in 1946 as the second
exclusive drug for the treatment of tuberculosis (TB). While PAS was initially a first-line TB …

Synthetic fluorescent protein chromophores have been reported for their singlet state
fluorescence properties and applications in bioimaging, but rarely for the triplet state …

A combination of chemical genetic and biochemical assays was applied to investigate the
mechanism of action of the anticancer drug 5-fluorouracil (5-FU), against Mycobacterium …

High through put screening (HTS) was extensively used in attempts to discover new TB
drugs from libraries of pure small molecule compounds many of which complied with the …

A safer treatment for toxoplasmosis would be achieved by improving the selectivity and
potency of dihydrofolate reductase (DHFR) inhibitors, such as pyrimethamine (1), for …